Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published May 1990 | public
Journal Article

Activation of interleukin-6 gene expression through the NF-κB transcription factor

Abstract

The promoter region of the interleukin-6 (IL-6) gene has a putative NF-κB-binding site. We found that a fragment of the IL-6 promoter containing the site specifically binds highly purified NF-κB protein and the NF-κB protein in nuclear extracts of phorbol ester-induced Jurkat cells. Mutations of the NF-κB site abolished complex formation with both purified NF-κB and the nuclear extract protein. Transient expression of chloramphenicol acetyltransferase (CAT) plasmids containing the IL-6 promoter revealed very little activity of the promoter in U-937 monocytic cells and in HeLa cells before stimulation. However, stimulation of U-937 and HeLa cells by inducers of NF-κB led to a dramatic increase in CAT activity. Mutations in the NF-κB-binding site abolished inducibility of IL-6 promoter-cat constructs in U-937 cells by lipopolysaccharide, tumor necrosis factor α, the double-stranded RNA poly(IC), or phytohemagglutinin and in HeLa cells by tumor necrosis factor alpha and drastically reduced but did not completely eliminate inducibility in HeLa cells stimulated by double-stranded RNA poly(IC) or phorbol 12-myristate 13-acetate. These results suggest that NF-κB is an important mediator for activation of the IL-6 gene by a variety of IL-6 inducers in both U-937 and HeLa cells and that alternative inducible enhancer elements contribute in a cell-specific manner to IL-6 gene induction. Because NF-κB is involved in the control of a variety of genes activated upon inflammation, NF-κB may play a central role in the inflammatory response to infection and tissue injury.

Additional Information

© 1990 American Society for Microbiology. Received 11 December 1989/Accepted 31 January 1990 We thank Patrick Baeuerle for helpful discussions and the kind gift of affinity-purified NF-κB. This work was supported by a fellowship from the Leukemia Society of America (T.A.L.) and Public Health Service grant GM 39458 to D.B. from the National Institutes of Health.

Additional details

Created:
August 19, 2023
Modified:
October 20, 2023